Clinical characteristics and prognostic factors of fibrotic nonspecific interstitial pneumonia

被引:9
作者
Cho, Hyun Kyu [2 ]
Chung, Man Pyo [1 ]
Lee, Kyung Soo [3 ]
Chung, Myung Jin [4 ,5 ]
Han, Joungho [6 ]
Kwon, O. Jung [1 ]
Yoo, Hongseok [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Pulm & Crit Care Med, 81 Irwon Ro, Seoul 06351, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Med,Div Pulm & Crit Care Med, Chang Won, South Korea
[3] Sungkyunkwan Univ, Samsung Changwon Hosp, Dept Radiol, Sch Med, Chang Won, South Korea
[4] Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiol, Sch Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Samsung Med Ctr, Ctr Imaging Sci, Sch Med, Seoul, South Korea
[6] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol, Sch Med, Seoul, South Korea
关键词
fibrotic nonspecific interstitial pneumonia; progression; relapse; survival; CLASSIFICATION CRITERIA; SURVIVAL; COLLEGE; LEAGUE;
D O I
10.1177/17534666221089468
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Aim: Several studies have reported favorable outcomes of nonspecific interstitial pneumonia (NSIP); however, its prognosis and prognostic factors remain unclear. This study aimed to determine the outcomes of fibrotic NSIP and the prognostic factors for progression, relapse, and survival. Methods: In this retrospective study, we reviewed the clinical data of 204 patients diagnosed with fibrotic NSIP by surgical lung biopsy at Samsung Medical Center. The factors associated with survival and disease progression or relapse were determined using Cox proportional hazard analysis. Results: The median age of patients was 54years and 67 (33%) patients were male. Also, 47 patients (23%) were current or ex-smokers. In all, 141 (69%) patients were diagnosed with idiopathic NSIP, while 63 (31%) patients were associated with connective tissue diseases. Progression or relapse was observed in 100 (49%) patients. The 5-year and 10-year survival rates were 94.6% and 90.4%, respectively. The factors associated with disease progression and relapse were diffusing capacity for carbon monoxide (DLco) <60% [adjusted hazard ratio (HR), 1.739; 95% confidence interval (CI), 1.036-2.921; p=0.036], bronchoalveolar lavage (BAL) lymphocyte >15% (adjusted HR, 0.592; 95% CI, 0.352-0.994; p=0.047), and treatment with corticosteroid and azathioprine (adjusted HR, 0.556; 95% CI, 0.311-0.955; p=0.048). Disease progression or relapse was associated with mortality (adjusted HR, 7.135; 95% CI, 1.499-33.971; p=0.014). Conclusion: Preserved lung function, BAL lymphocytosis, and treatment with corticosteroids and azathioprine were associated with lower risks of disease progression and relapse, which were risk factors for mortality.
引用
收藏
页数:11
相关论文
共 33 条
[1]  
Brown KK, 2020, EUR RESPIR J, V55
[2]   Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases [J].
Chen, Xianqiu ;
Guo, Jian ;
Yu, Dong ;
Jie, Bing ;
Zhou, Ying .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[3]   Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases [J].
Cottin, Vincent ;
Hirani, Nikhil A. ;
Hotchkin, David L. ;
Nambiar, Anoop M. ;
Ogura, Takashi ;
Otaola, Maria ;
Skowasch, Dirk ;
Park, Jong Sun ;
Poonyagariyagorn, Hataya K. ;
Wuyts, Wim ;
Wells, Athol U. .
EUROPEAN RESPIRATORY REVIEW, 2018, 27 (150)
[4]   Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris [J].
Duchemann, Boris ;
Annesi-Maesano, Isabella ;
de Naurois, Camille Jacobe ;
Sanyal, Shreosi ;
Brillet, Pierre-Yves ;
Brauner, Michel ;
Kambouchner, Marianne ;
Huynh, Sophie ;
Naccache, Jean Marc ;
Borie, Raphael ;
Piquet, Jacques ;
Mekinian, Arsene ;
Virally, Jerome ;
Uzunhan, Yurdagul ;
Cadranel, Jacques ;
Crestani, Bruno ;
Fain, Olivier ;
Lhote, Francois ;
Dhote, Robin ;
Saidenberg-Kermanac'h, Nathalie ;
Rosental, Paul-Andre ;
Valeyre, Dominique ;
Nunes, Hilario .
EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (02)
[5]   Lung CT: Part 2, The Interstitial Pneumonias-Clinical, Histologic, and CT Manifestations [J].
Ferguson, Emma C. ;
Berkowitz, Eugene A. .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2012, 199 (04) :W464-W476
[6]   Nintedanib in Progressive Fibrosing Interstitial Lung Diseases [J].
Flaherty, K. R. ;
Wells, A. U. ;
Cottin, V ;
Devaraj, A. ;
Walsh, S. L. F. ;
Inoue, Y. ;
Richeldi, L. ;
Kolb, M. ;
Tetzlaff, K. ;
Stowasser, S. ;
Coeck, C. ;
Clerisme-Beaty, E. ;
Rosenstock, B. ;
Quaresma, M. ;
Haeufel, T. ;
Goeldner, R-G ;
Schlenker-Herceg, R. ;
Brown, K. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) :1718-1727
[7]   The 2016 classification criteria for primary Sjogren's syndrome: what's new? [J].
Franceschini, Franco ;
Cavazzana, Ilaria ;
Andreoli, Laura ;
Tincani, Angela .
BMC MEDICINE, 2017, 15
[8]   Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease [J].
Huapaya, Julio ;
Silhan, Leann ;
Pinal-Fernandez, Iago ;
Casal-Dominguez, Maria ;
Johnson, Cheilonda ;
Albayda, Jemima ;
Paik, Julie ;
Sanyal, Abanti ;
Mammen, Andrew ;
Christopher-Stine, Lisa ;
Danoff, Sonye .
CHEST, 2019, 156 (05) :896-906
[9]  
KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
[10]   Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: Classification and diagnostic criteria [J].
Katzenstein, ALA ;
Myers, JL .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (01) :1-3